Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have lung cancer that is mostly not “squamous” type.
- After surgery, your cancer must be classified as Stage IB, II, or IIIA using pathology (surgical lab) results.
- Your tumor test must show an EGFR mutation such as Ex19del or L858R (and may include other EGFR changes).
- Your lung tumor must be completely removed with no visible disease left, with negative (clear) surgical margins.
- You must be well enough to do normal activities (Performance Status 0–1) and fully recovered from surgery and any standard post-op treatment.
- You must not have had any prior cancer treatment for this cancer (including chemotherapy or EGFR medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a targeted drug (furmonertinib) combined with other treatments before surgery for lung cancer with an EGFR mutation. The goal is to shrink the tumor and make surgery more effective.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Hear when a new Non-small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.